Loading...
629. AGGRESSIVE LYMPHOMAS, IMMUNOTHERAPY INCLUDING BISPECIFIC ANTIBODIES Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (Car T) therapy from the 3-year follow-up
Thieblemont, C. Jurczak, W. Kim, T. M. Linton, K. Cheah, C. Jiang, J. Y. Atiya, M. Eskelund, C. Woods, D. Phillips, T.
Thieblemont, C.
Jurczak, W.
Kim, T. M.
Linton, K.
Cheah, C.
Jiang, J. Y.
Atiya, M.
Eskelund, C.
Woods, D.
Phillips, T.
Abstract
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 170.33 KB
Keywords
Type
Article
Citation
Thieblemont C, Jurczak W, Kim TM, Linton K, Cheah C, Jiang JY, et al. 629. AGGRESSIVE LYMPHOMAS, IMMUNOTHERAPY INCLUDING BISPECIFIC ANTIBODIES Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up. Blood. 2025 NOV 3;146:1960-1.